VALIDATE confirms high sensitivity of the CADScor®System

For the first time, the usage of the CADScor® System in a high prevalence cohort is described by M. Renker et al. This prospective randomized cohort was designed as technical study to confirm predicted sensitivity and specificity in a high prevalence patient group (not the intended patient group for the CADScor®System in clinical practice). Use of the CADScor®System allowed the identification of individuals with CAD in a high-prevalence cohort with a high sensitivity of 97.6% but with a lower specificity. The negative predictive value of 90.5% was within the predicted range for a high-prevalence cohort. The results were intended to be presented during the annual meeting of the German cardiac society and are published as poster abstract.

Poster Abstract>>https://www.abstractserver.com/dgk2020/jt/abstracts/P1850.htm

About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.